The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Key Findings Reviewed From ALCYONE Trial in Myeloma

Maria-Victoria Mateos, MD, PhD
Published Online: 8:06 PM, Mon December 3, 2018


Maria-Victoria Mateos, MD, PhD, a physician and director of the myeloma program at the University of Salamanca, Spain, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib (Velcade), melphalan, and prednisone (VMP) in combination with daratumumab (Darzalex; DARA; D-VMP) in patients with newly diagnosed multiple myeloma who are transplant ineligible. 

After a median follow-up of 28 months, D-VMP was superior to VMP in terms of overall response rate, complete response rate, and progression-free survival (PFS), Mateos says. PFS acted as a surrogate marker for overall survival. 

DARA was also analyzed as a maintenance after D-VMP treatment, and this was shown to have an effect on the quality of responses, Mateos adds.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.